

Orthocell key scaffold patent granted in Canada

- Canadian patent granted for collagen scaffolds combined with tenocytes for tendon regeneration
- Granted Canadian Patent Application No. 2685146 entitled “Tenocyte containing bioscaffolds and treatments using the same”

Perth, Australia; 9 December 2015: Regenerative medicine company Orthocell Limited has today announced it has been granted a patent in Canada covering the combination of bio-scaffolds and tenocytes, the cells that make up healthy tendons.

The patents are described as Canadian Patent Application No. 2685146 “Tenocyte containing bioscaffolds and treatments using the same”.

The granting of these patents further complements Orthocell’s patent family covering cells scaffolds and combinations. This patent follows already granted patents in the USA, Singapore, China and New Zealand to provide a solid IP foundation for both cellular therapy for tendon regeneration and for the collagen based medical device Celgro™.

Orthocell Managing Director Paul Anderson said: “Our patent family is continuing to grow and provide us with surety around our products and product development, ensuring a solid foundation for the partnering and licencing of our technologies.”

The latest patent relates to the combination of cells and scaffolds to form a regenerative construct for tendons. This patent strongly complements Orthocell’s current Ortho-ATI™ injectable cell therapy for degenerate tendons and collagen based soft tissue medical device Celgro™.

The patent, together with the other granted family members in Australia, China, New Zealand and Singapore, will expire on 24 April 2028.

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited, Managing Director
P: (08) 9360 2888
E: paulanderson@orthocell.com.au

Investor Relations

Buchan Consulting
Ben Walsh
P: 0468 422 865
E: bwalsh@buchanwe.com.au

About Orthocell Limited

Orthocell is a commercial-stage, regenerative medicine company focused on developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell's portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.